✦ LIBER ✦

Cancer therapeutic antibodies come of age: Targeting minimal residual disease

✍ Scribed by Tsipi Ben-Kasus; Bilha Schechter; Michael Sela; Yosef Yarden

Book ID: 119328783
Publisher: Wiley (John Wiley & Sons)
Year: 2007
Tongue: English
Weight: 657 KB
Volume: 1
Category: Article
ISSN: 1574-7891
DOI: 10.1016/j.molonc.2007.01.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Minimal residual disease as the target f

Minimal residual disease as the target for immunotherapy of cancer

✍ G.J.V. Nossal 📂 Article 📅 1994 🏛 The Lancet 🌐 English ⚖ 552 KB

The minimal residual disease concept com

The minimal residual disease concept coming of age – Now for the direct comparison of methodologies

✍ Hans Beier Ommen; Anne Stidsholt Roug; Peter Hokland 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 169 KB

Single-dose intraperitoneal radioimmunot

Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancer

✍ F. Crippa; G. Bolis; E. Seregni; N. Gavoni; G. Scarfone; C. Ferraris; G.L. Burag 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 621 KB

Targeted therapy with the T-cell - Engag

Targeted therapy with the T-cell - Engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival

✍ Topp, Max S. (author);Kufer, Peter (author);Gökbuget, Nicola (author);Goebeler, 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 135 KB

Targeted therapy with the T-cell - Engag

✍ Topp, Max S. (author);Kufer, Peter (author);Gökbuget, Nicola (author);Goebeler, 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 135 KB